Table 1 Comparison of patient's characteristics between the two periods
2013–2016 | 2017–2020 | p | |
|---|---|---|---|
(n = 86) | (n = 183) | ||
Age | 45 (30–59.3) | 45.3 (32.6–61.5) | 0.458 |
Gender—female | 63 (73.3%) | 125 (68.3%) | 0.409 |
Comorbidities | |||
Diabetes | 6 (7%) | 31 (16.9%) | 0.027 |
Ischemic heart disease | 6 (7%) | 15 (8.2%) | 0.728 |
Congestive heart failure | 2 (2.3%) | 6 (3.3%) | > 0.999 |
Chronic renal failure | 4 (4.7%) | 3 (1.6%) | 0.215 |
Allergy | |||
No allergy | 74 (86%) | 156 (85.2%) | 0.968 |
Penicillin | 12 (14%) | 23 (12.6%) | |
Clarithromycin | 0 (0%) | 1 (0.5%) | |
Tetracycline | 0 (0%) | 2 (1.1%) | |
Penicillin and clarithromycin | 0 (0%) | 1 (0.5%) | |
Previous antibiotics received | |||
Previously treated | 77 (89.5%) | 135 (73.8%) | 0.003 |
Naïve not treated | 9 (10.5%) | 48 (26.2%) | |
Antibiotic received | |||
Amoxicillin | 63 (73.3%) | 112 (61.2%) | 0.053 |
Clarithromycin | 75 (87.2%) | 121 (66.1%) | < 0.001 |
Metronidazole | 53 (61.6%) | 89 (48.6%) | 0.046 |
Tetracycline | 45 (52.3%) | 58 (31.7%) | 0.001 |
Bismuth | 44 (51.2%) | 56 (30.6%) | 0.001 |
Levofloxacin | 15 (17.4%) | 24 (13.1%) | 0.374 |
Rifabutin | 1 (1.2%) | 2 (1.1%) | > 0.999 |